Autopsy report · NCT04770272

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

“The trial stopped recruitment prematurely after a first planned interim analysis of the first 100 pCR results (given that a probability of less than 2.5% of meeting the primary endpoint was estimated).”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 7 months before it stopped.
• 442 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Palleos Healthcare GmbH

Sponsor type

Industry

Conditions

Triple-negative Breast Cancer

Interventions

Atezolizumab 840 MG in 14 ML Injection; Atezolizumab 1200 MG in 20 ML Injection; Carboplatin; Paclitaxel; Epirubicin; Cyclophosphamide

Participants

442

Sites

1

Countries

Germany

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.